Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(3 sites)
Japan
GSK Investigational Site, Fukuoka GSK Investigational Site, Hiroshima GSK Investigational Site, Hokkaido